Annals of Surgical Oncology

, Volume 26, Issue 13, pp 4619–4620 | Cite as

ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma?

  • Daniel W. Nelson
  • Mark B. FariesEmail author
ASO Author Reflections



There are no conflicts of interest.


  1. 1.
    Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24:3991–4000.CrossRefGoogle Scholar
  2. 2.
    Nelson D, Fischer T, Graff-Baker A, Dehal A, Stern S, Bilchik A, Faries M. Impact of effective systemic therapy on metastasectomy in stage IV melanoma: a matched-pair analysis. Ann Surg Oncol. 2019. Scholar
  3. 3.
    Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17:1743–54.CrossRefGoogle Scholar
  4. 4.
    Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60–5.CrossRefGoogle Scholar
  5. 5.
    Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–23.CrossRefGoogle Scholar
  6. 6.
    Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryWilliam Beaumont Army Medical CenterEl PasoUSA
  2. 2.Division of Surgical OncologyThe Angeles Clinic and Research InstituteLos AngelesUSA
  3. 3.Department of SurgeryCedars Sinai Medical CenterLos AngelesUSA

Personalised recommendations